We are live on ! Find out more
LIPO

Lipella Pharmaceuticals
LIPO

Delisted

LIPO was delisted on the 18th of June, 2025.

Back to rankings

3 hedge funds and large institutions have $7.13K invested in Lipella Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

1% less ownership

Funds ownership: 1.11% → 0.11% (-1%)

83% less capital invested

Capital invested by funds: $41.4K → $7.13K (-$34.3K)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$7.87K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$41K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
1
Tower Research Capital (TRC)
New York
$6.8K +$7.87K +2,708 New
MCM
2
MAI Capital Management
Ohio
$314 – – –
Bank of America
3
Bank of America
North Carolina
$18 – – –
VF
4
Virtu Financial
New York
– -$41K -13,310 Closed

LIPO Hedge Fund Activity: Q1 2025 in Review

3 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q1 2025, worth a combined $7.13K — down 83% from $41.4K a quarter earlier.

Fund positioning in LIPO was balanced in Q1 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $7.87K. The largest seller was Virtu Financial, exiting entirely with an estimated $41K sold.

  • 3 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $7.13K of Lipella Pharmaceuticals stock for Q1 2025, down 83% quarter-over-quarter.
  • 1 fund opened new Lipella Pharmaceuticals positions in Q1 2025 and 1 closed out, a net change of 0 holders.
  • The largest Lipella Pharmaceuticals buyer in Q1 2025 was Tower Research Capital (TRC), an estimated $7.87K added.
  • The largest Lipella Pharmaceuticals seller in Q1 2025 was Virtu Financial, an estimated $41K sold.

Based on aggregated 13F filings for Q1 2025.